Journal
LEUKEMIA & LYMPHOMA
Volume 62, Issue 3, Pages 606-613Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/10428194.2020.1839651
Keywords
Pediatric Hodgkin lymphoma; LAG-3; immune checkpoint; immunotherapy
Categories
Funding
- St. Baldrick's Foundation
- Children's Oncology Group Foundation NCTN ITSC-Hematopoietic Malignancies Grant [UG1CA233249]
- National Cancer Institute [U10 CA98543]
- NCTN Operations Center Grant [U10CA180886]
- NCTN Statistics & Data Center Grant [U10CA180899]
Ask authors/readers for more resources
In pediatric Hodgkin lymphoma, LAG-3 expression is found to be positively correlated with PD-L1 expression, serving as an innovative immune checkpoint target with unclear association to patient outcomes.
LAG-3, through interaction with a variety of ligands, regulates T cell function via inhibition of T cell proliferation and activation. It has been demonstrated to be overexpressed on tumor infiltrating lymphocytes (TILs) of a variety of cancers with associated poor outcomes. The purpose of this study is to characterize the expression pattern and clinical significance of LAG-3 in pediatric Hodgkin lymphoma (HL). Patient tumor samples from Children's Oncology Group clinical trial AHOD0031 with matched patient outcome data were analyzed for the expression of LAG-3 and PD-L1 using immunohistochemistry. 73/115 patients (63%) demonstrated positive LAG-3 staining. No demographic or survival outcome data were significantly associated with LAG-3 expression. Interestingly, patients with the lowest density of expression were found to have the worst EFS, and those with highest density of expression demonstrated the best EFS. There was a positive statistically significant relationship between presence of LAG-3 and PD-L1 expression. This project is innovative in its characterization of LAG-3 as an immune checkpoint target in pediatric HL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available